Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study

Am Rev Respir Dis. 1981 Feb;123(2):165-70. doi: 10.1164/arrd.1981.123.2.165.

Abstract

We compared the bacteriologic relapse between 5 and 28 months for five 4-month chemotherapeutic regimens for pulmonary tuberculosis. The regimens were: (1) streptomycin plus isoniazid plus rifampin plus pyrazinamide daily for 8 wk followed by isoniazid plus rifampin plus pyrazinamide daily for 9 wk; (2) the same 4 initial drugs for 8 wk followed by isoniazid plus rifampin daily for 9 wk; (3) the same 4 initial drugs for 8 wk followed by isoniazid plus pyrazinamide daily for 9 wk; (4) the same 4 drugs for 8 wk followed by isoniazid daily for 9 wk; (5) the same as regimen 4; but without streptomycin for the first 8 wk. The first 2 regimens, in which rifampin was given for 4 months, had relapse rates of 16 and 11%, respectively, but the rates were much higher for the regimens in which rifampin was given for only 2 months (32 and 30 %, respectively). The addition of pyrazinamide in the continuation phase had no effect on relapse rate. Removal of the streptomycin (regimen 5) resulted in a relapse rate of 40%, but this was not significantly higher than that (30%) after regimen 4 (p = 0.2).

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antitubercular Agents / administration & dosage*
  • Clinical Trials as Topic
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Humans
  • Isoniazid / administration & dosage
  • Isoniazid / therapeutic use
  • Middle Aged
  • Pyrazinamide / administration & dosage
  • Pyrazinamide / therapeutic use
  • Random Allocation
  • Recurrence
  • Rifampin / administration & dosage
  • Rifampin / therapeutic use
  • Streptomycin / administration & dosage
  • Streptomycin / therapeutic use
  • Tuberculosis, Pulmonary / drug therapy*

Substances

  • Antitubercular Agents
  • Pyrazinamide
  • Isoniazid
  • Rifampin
  • Streptomycin